141 related articles for article (PubMed ID: 38276907)
1. Primary Axillary Vein Leiomyosarcoma in Li-Fraumeni Syndrome.
Roslly MZ; Omar N; Naim MS
Radiol Imaging Cancer; 2024 Jan; 6(1):e230184. PubMed ID: 38276907
[No Abstract] [Full Text] [Related]
2. Primary Cutaneous Leiomyosarcoma Arising in a Patient With Li-Fraumeni Syndrome: A Neoplasm With Unusual Histopathologic Features and Loss of Heterozygosity at TP53 Gene.
Sabater-Marco V; Ferrando-Roca F; Morera-Faet A; García-García JA; Bosch SB; López-Guerrero JA
Am J Dermatopathol; 2018 Mar; 40(3):225-227. PubMed ID: 28475508
[No Abstract] [Full Text] [Related]
3. Rectal leiomyosarcoma as the initial phenotypic manifestation of Li-Fraumeni-like syndrome: a case report and review of the literature.
Severino NP; Waisberg J; Fragoso MCBV; de Lima LGCA; Balsamo F; Henriques AC; Bianco B; de Sousa Gehrke F
J Med Case Rep; 2022 Dec; 16(1):468. PubMed ID: 36529791
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and imaging surveillance in Li-Fraumeni syndrome.
Raskind WH; Hisama FM; Bennett RL
Lancet Oncol; 2016 Nov; 17(11):e472. PubMed ID: 27819239
[No Abstract] [Full Text] [Related]
5. Biochemical and imaging surveillance in Li-Fraumeni syndrome - Authors' reply.
Villani A; Malkin D
Lancet Oncol; 2016 Nov; 17(11):e473. PubMed ID: 27819240
[No Abstract] [Full Text] [Related]
6. Surveillance of Dutch Patients With Li-Fraumeni Syndrome: The LiFe-Guard Study.
Ruijs MWG; Loo CE; van Buchem CAJM; Bleiker EMA; Sonke GS
JAMA Oncol; 2017 Dec; 3(12):1733-1734. PubMed ID: 28772294
[TBL] [Abstract][Full Text] [Related]
7. Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.
Nemunaitis JM; Nemunaitis J
Future Oncol; 2008 Dec; 4(6):759-68. PubMed ID: 19086841
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of the prevalence of autoimmune disorders in Li-Fraumeni syndrome.
Obregón IH; de Andrade KC; Bremer RC; Khincha PP; Savage SA
Fam Cancer; 2023 Jul; 22(3):319-321. PubMed ID: 36627407
[No Abstract] [Full Text] [Related]
9. Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial.
Caron O; Frebourg T; Benusiglio PR; Foulon S; Brugières L
JAMA Oncol; 2017 Dec; 3(12):1736-1737. PubMed ID: 28772306
[TBL] [Abstract][Full Text] [Related]
10. Li-Fraumeni syndrome.
Ossa CA; Molina G; Cock-Rada AM
Biomedica; 2016 Jun; 36(2):182-7. PubMed ID: 27622479
[TBL] [Abstract][Full Text] [Related]
11. [TP53 germline mutation related Li-Fraumeni syndrome: report of a case].
Liu XL; Jin XF; Song YL; Li GQ; Lin DL; Xing XM
Zhonghua Bing Li Xue Za Zhi; 2022 May; 51(5):458-460. PubMed ID: 35511646
[TBL] [Abstract][Full Text] [Related]
12. Third international workshop on collaborative interdisciplinary studies of p53 and other predisposing genes in Li-Fraumeni syndrome.
Eng C; Schneider K; Fraumeni JF; Li FP
Cancer Epidemiol Biomarkers Prev; 1997 May; 6(5):379-83. PubMed ID: 9149899
[No Abstract] [Full Text] [Related]
13. p53 and the Li-Fraumeni syndrome.
Malkin D
Cancer Genet Cytogenet; 1993 Apr; 66(2):83-92. PubMed ID: 8500106
[TBL] [Abstract][Full Text] [Related]
14. The Li-Fraumeni syndrome: an inherited susceptibility to cancer.
Evans SC; Lozano G
Mol Med Today; 1997 Sep; 3(9):390-5. PubMed ID: 9302689
[TBL] [Abstract][Full Text] [Related]
15. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
16. 2009 version of the Chompret criteria for Li Fraumeni syndrome.
Tinat J; Bougeard G; Baert-Desurmont S; Vasseur S; Martin C; Bouvignies E; Caron O; Bressac-de Paillerets B; Berthet P; Dugast C; Bonaïti-Pellié C; Stoppa-Lyonnet D; Frébourg T
J Clin Oncol; 2009 Sep; 27(26):e108-9; author reply e110. PubMed ID: 19652052
[No Abstract] [Full Text] [Related]
17. Heterogeneity in Li-Fraumeni families: p53 mutation analysis and immunohistochemical staining.
MacGeoch C; Turner G; Bobrow LG; Barnes DM; Bishop DT; Spurr NK
J Med Genet; 1995 Mar; 32(3):186-90. PubMed ID: 7783166
[TBL] [Abstract][Full Text] [Related]
18. Genotype Versus Phenotype: The Yin and Yang of Germline TP53 Mutations in Li-Fraumeni Syndrome.
Nichols KE; Malkin D
J Clin Oncol; 2015 Jul; 33(21):2331-3. PubMed ID: 26101242
[No Abstract] [Full Text] [Related]
19. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.
Bojadzieva J; Amini B; Day SF; Jackson TL; Thomas PS; Willis BJ; Throckmorton WR; Daw NC; Bevers TB; Strong LC
Fam Cancer; 2018 Apr; 17(2):287-294. PubMed ID: 28988289
[TBL] [Abstract][Full Text] [Related]
20. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
